Compare Match Group Inc (MTCH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs TransMedics Group Inc — how do they compare? Match Group Inc trades at $36.51 (market cap $8.45B), while TransMedics Group Inc trades at $87.55 (market cap $3.10B). The key difference: Match Group Inc is far larger — about 2.7× TransMedics Group Inc's market cap, and Match Group Inc pays a 2.17% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MTCH | TMDX | |
|---|---|---|
Market Cap | $8.45B | $3.10B |
Sector | Media | Technology |
52-Week High | $41.24 | $150.42 |
52-Week Low | $28.90 | $61.99 |
Enterprise Value | $11.42B | $3.49B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Match Group (MTCH) trades at $36.36, down 1.01% on the day, with a bearish technical signal but neutral oscillators. The company reported mixed Q2 2026 results, missing revenue estimates but beating EPS, with Tinder showing engagement improvements and Hinge growing revenue 22% year-over-year. Financials indicate strong profitability with a net income margin of 20.17% and a P/E ratio of 13.05, while cash flow trends show positive net cash flow in 2025. Recent news highlights institutional buying and Zacks rankings for growth, income, and value stocks.
The outlook for MTCH is cautiously optimistic, with analyst consensus pointing to a $42.33 price target and no sell ratings. Risks include Tinder's sluggish performance and high debt levels, but opportunities lie in Hinge's expansion and product innovation. Investors should weigh solid fundamentals against competitive and execution risks in the dating app market.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
